CYP2C19 and androgen insensitivity syndrome: On the one hand, patients with ICH who possessed APOE4 allele had a 2.6-fold increase in poor outcome; on the other hand, poor outcome was increased among patients with AIS who possessed poor metaboliser variants (CYP2C19 *2, CYP2C19 *3 and CYP2C19 *17) by 2.4-fold and those who carried BDNF GA or AA genotypes by 1.6-fold, but not in patients with AIS who possessed APOE4 or IL6 alleles.